CTOs on the Move

Adaptive Biotechnologies

www.adaptivebiotech.com

 
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people`s lives by learning from the wisdom of their adaptive immune systems. Adaptive`s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
David Arbo
 Sr Director of Information Technology Profile
Josh Schmidt
 Senior Director, Information Security Profile
Mark Adams
 Chief Technical Officer Profile
Mark Adams
 Chief Operating Officer Profile

Funding

Adaptive Biotechnologies raised $195M on 05/07/2015

Similar Companies

Linnaeus Therapeutics

Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.

Clinical Trials Services

Clinical Trials Services is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evolution Medical Communications

Evolution Medical Communications, LLC is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Woodcock Washburn

Woodcock Washburn is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GABA Therapeutics,

A New Dawn for Central Nervous System Treatments GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal to no side effects. The drugs dual mechanism of action may also benefit ...